Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
Abstract Background Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) incidence has been increasing in the United States for greater than 30 years. For the majority of EAC patients, treatment is limited and prognosis poor. Doublecortin like kinase-1 (DCLK1) is a cancer stem cell marker wi...
Main Authors: | Emily M. Christman, Parthasarathy Chandrakesan, Nathaniel Weygant, John T. Maple, William M. Tierney, Kenneth J. Vega, Courtney W. Houchen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40364-019-0157-z |
Similar Items
-
Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation
by: Pengming Pan, et al.
Published: (2024-12-01) -
Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment
by: Zhiyun Cao, et al.
Published: (2020-12-01) -
Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells
by: Landon L. Moore, et al.
Published: (2023-11-01) -
Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments
by: Xiangyan Wu, et al.
Published: (2020-01-01) -
Alzheimer hastalığında doublecortin-like kinaz-1 düzeyleri ve oksidan durumu
by: Savaş GÜZEL, et al.
Published: (2017-12-01)